TCT ’22: Medtronic Rolls Out Evolut FX TAVR

Medtronic began expanded U.S. market release for its newest Evolut FX self-expanding transcatheter aortic valve replacement (TAVR) system at this year’s Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.
 
Full release follows the recent U.S. Food and Drug Administration (FDA) approval and limited rollout earlier this year.
 
Evolut FX includes gold markers built into the frame so implanters have direct visualization of commissure alignment. A redesigned catheter tip creates a smoother insertion profile. Its more flexible delivery system has an optimized stability layer for more stable, predictable deployment. Like its Evolut PRO+ predecessor, Evolut FX has four valve sizes for the largest patient treatment range and lowest delivery profile on the market, according to Medtronic.
 
“This represents a milestone for our structural heart business, as we look to set new expectations for TAVR delivery systems and optimize outcomes for patients. These innovations will equip physicians with improved implant predictability, ultimately improving the overall reliability of the procedure,” Jeffrey Popma, M.D., VP and chief medical officer for Medtronic’s Structural Heart & Aortic business told the press.